Kānuka Extract Offers Potential to Mitigate Side Effects of Organ Transplant Medications

Recent research has revealed that a compound found in the native kānuka plant, indigenous to Aotearoa New Zealand, may help reduce the adverse side effects associated with the immunosuppressant drug rapamycin, commonly used in kidney transplant patients. The compound, identified as nerolidol, is present in an extract derived from kānuka and shows promising potential when used in combination with rapamycin.

Studies suggest that nerolidol could enhance the body's absorption of rapamycin, potentially allowing for lower dosages to be administered. This approach could decrease the likelihood of side effects such as anemia, hyperglycemia, and kidney complications, which are often linked to higher doses of rapamycin.

Dr. Andrew Munkacsi, from Victoria University of Wellington, highlighted that while more research and clinical trials are necessary, preliminary findings are encouraging in demonstrating giảm in rapamycin toxicity. The research also emphasizes the cultural significance of kānuka and its historical use by Māori communities, while exploring its modern medicinal potential.

The project is part of a long-standing partnership between the university and Hikurangi Bioactives, a company based in Ruatōria that develops products from kānuka oil. The collaboration involves Māori landowners in sourcing raw materials and sharing the benefits of the research. Landowner Bella Paenga expressed pride in the community’s involvement and the prospects of developing sustainable industries that honor indigenous knowledge.

This research not only illuminates new therapeutic applications for kānuka but also exemplifies respectful partnerships with Indigenous communities. Experts advocate increasing investments in native plant research to uncover further health benefits.

Source: https://medicalxpress.com/news/2025-05-knuka-transplant-medication-side-effects.html